دورية أكاديمية
أعرض في EDS

Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up.

التفاصيل البيبلوغرافية
العنوان: Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up.
المؤلفون: van den Berg JH; BioTherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., Heemskerk B; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Rooij N; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Gomez-Eerland R; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Michels S; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Zon M; BioTherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., de Boer R; BioTherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., Bakker NAM; BioTherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., Jorritsma-Smit A; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Buuren MM; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Kvistborg P; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Spits H; AIMM Therapeutics, Amsterdam, The Netherlands.; Experimental Immunology, Amsterdam University Medical Centres, Amsterdam, Noord-Holland, The Netherlands., Schotte R; AIMM Therapeutics, Amsterdam, The Netherlands., Mallo H; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Karger M; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Hage JA; Department of Surgery, Leiden Universitair Medisch Centrum, Leiden, Zuid-Holland, The Netherlands., Wouters MWJM; Surgical Oncology, Antoni van Leeuwenhoek Nederlands Kanker Instituut, Amsterdam, The Netherlands.; Dutch Institute for Clinical Auditing, Leiden, The Netherlands., Pronk LM; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Geukes Foppen MH; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Blank CU; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, The Netherlands., Beijnen JH; Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University Department of Pharmaceutical Sciences, Utrecht, Utrecht, The Netherlands., Nuijen B; Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Schumacher TN; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Haanen JBAG; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands j.haanen@nki.nl.
المصدر: Journal for immunotherapy of cancer [J Immunother Cancer] 2020 Aug; Vol. 8 (2).
نوع المنشور: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: 2020- : London, United Kingdom : BMJ Publishing Group Ltd.
Original Publication: London : BioMed Central, 2013-
مواضيع طبية MeSH: Lymphocytes, Tumor-Infiltrating/*metabolism , Melanoma/*genetics , T-Lymphocytes/*metabolism, Adult ; Aged ; Female ; Follow-Up Studies ; Humans ; Male ; Melanoma/pathology ; Middle Aged
مستخلص: Treatment of metastatic melanoma with autologous tumor infiltrating lymphocytes (TILs) is currently applied in several centers. Robust and remarkably consistent overall response rates, of around 50% of treated patients, have been observed across hospitals, including a substantial fraction of durable, complete responses.
Purpose: Execute a phase I/II feasibility study with TIL therapy in metastatic melanoma at the Netherlands Cancer Institute, with the goal to assess feasibility and potential value of a randomized phase III trial.
Experimental: Ten patients were treated with TIL therapy. Infusion products and peripheral blood samples were phenotypically characterized and neoantigen reactivity was assessed. Here, we present long-term clinical outcome and translational data on neoantigen reactivity of the T cell products.
Results: Five out of 10 patients, who were all anti-PD-1 naïve at time of treatment, showed an objective clinical response, including two patients with a complete response that are both ongoing for more than 7 years. Immune monitoring demonstrated that neoantigen-specific T cells were detectable in TIL infusion products from three out of three patients analyzed. For six out of the nine neoantigen-specific T cell responses detected in these TIL products, T cell response magnitude increased significantly in the peripheral blood compartment after therapy, and neoantigen-specific T cells were detectable for up to 3 years after TIL infusion.
Conclusion: The clinical results from this study confirm the robustness of TIL therapy in metastatic melanoma and the potential role of neoantigen-specific T cell reactivity. In addition, the data from this study supported the rationale to initiate an ongoing multicenter phase III TIL trial.
Competing Interests: Competing interests: JH has a research collaboration with BMS, MSD, Novartis and BionTech USA. JH serves as an advisor or consultant for: AIMM therapeutics, AZ, Amgen, Achilles TX, Bayer, BMS, GSK, Ipsen, Immunocore, MSD, Merck Serono, BionTech USA, Neogene Therapeutics, Novartis, Pfizer, Roche/Genentech, Sanofi, Seattle Genetics, Third Rock Ventures and Vaximm. TNS has a research collaboration with Merck KGaA. TNS serves as an adivisor or consultant for: Adaptive Biotechnologies, AIMM Therapeutics, Allogene Therapeutics, Merus, BionTech USA and Scenic Biotech. TNS is a stockholder of AIMM Therapeutics, Allogene Therapeutics, Merus, Neogene Therapeutics, BionTech USA and Scenic Biotech. AIMM Therapeutics holds IP to immortalize human B cells and the AT1412 antibody. HS and RS are employees of AIMM Therapeutics. RS and HS are stockholders of AIMM Therapeutics. The retroviral vectors containing BCL-6 and Bcl-xL have been generated by a for-profit company, AIMM Therapeutics, which makes the plasmids available. Obtaining the plasmids requires an MTA that includes financial obligations.
(© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
References: Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6458-62. (PMID: 8022805)
Nat Med. 2010 Jan;16(1):123-8. (PMID: 20023635)
Curr Protoc Immunol. 2009 Nov;Chapter 18:Unit 18.16. (PMID: 19918947)
J Immunother. 2011 Mar;34(2):212-20. (PMID: 21304398)
Science. 2014 May 9;344(6184):641-5. (PMID: 24812403)
Nat Med. 2013 Jun;19(6):747-52. (PMID: 23644516)
N Engl J Med. 2019 Oct 17;381(16):1535-1546. (PMID: 31562797)
Semin Oncol. 2015 Jun;42(3):466-73. (PMID: 25965365)
Cancer Res. 2001 Jul 15;61(14):5544-51. (PMID: 11454705)
J Exp Med. 1994 Jul 1;180(1):35-42. (PMID: 8006593)
Clin Cancer Res. 2016 Aug 1;22(15):3734-45. (PMID: 27006492)
J Clin Oncol. 2005 Apr 1;23(10):2346-57. (PMID: 15800326)
Nat Methods. 2009 Jul;6(7):520-6. (PMID: 19543285)
N Engl J Med. 2010 Aug 19;363(8):711-23. (PMID: 20525992)
J Immunol. 2013 Jun 15;190(12):6034-42. (PMID: 23690473)
N Engl J Med. 2015 Jun 25;372(26):2509-20. (PMID: 26028255)
Nat Commun. 2017 Nov 23;8(1):1738. (PMID: 29170503)
Clin Cancer Res. 2018 Sep 15;24(18):4416-4428. (PMID: 29848573)
Immunol Rev. 2006 Jun;211:214-24. (PMID: 16824130)
Clin Cancer Res. 2012 Dec 15;18(24):6758-70. (PMID: 23032743)
Cytotherapy. 2014 Aug;16(8):1117-20. (PMID: 24831841)
PLoS Comput Biol. 2012;8(3):e1002412. (PMID: 22396638)
J Clin Oncol. 2013 Nov 10;31(32):e439-42. (PMID: 24043743)
Clin Cancer Res. 2010 May 1;16(9):2646-55. (PMID: 20406835)
Curr Opin Immunol. 2009 Apr;21(2):233-40. (PMID: 19304471)
N Engl J Med. 2015 Jul 2;373(1):23-34. (PMID: 26027431)
Clin Cancer Res. 2011 Jul 1;17(13):4550-7. (PMID: 21498393)
Mol Immunol. 2015 Dec;68(2 Pt C):492-6. (PMID: 26256793)
Ann Oncol. 2018 Jul 1;29(7):1575-1581. (PMID: 29688262)
Clin Cancer Res. 2013 Sep 1;19(17):4792-800. (PMID: 23690483)
Nature. 2013 Aug 22;500(7463):415-21. (PMID: 23945592)
J Clin Oncol. 2012 Jul 20;30(21):2678-83. (PMID: 22711850)
Nat Med. 2015 Jan;21(1):81-5. (PMID: 25531942)
Oncoimmunology. 2012 Jul 1;1(4):409-418. (PMID: 22754759)
Lancet Oncol. 2015 Mar;16(3):257-65. (PMID: 25704439)
Clin Cancer Res. 2015 Jul 1;21(13):3052-60. (PMID: 25788491)
فهرسة مساهمة: Keywords: immunotherapy, adoptive; lymphocytes, tumor-infiltrating; melanoma
تواريخ الأحداث: Date Created: 20200806 Date Completed: 20210907 Latest Revision: 20210907
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC7406109
DOI: 10.1136/jitc-2020-000848
PMID: 32753545
قاعدة البيانات: MEDLINE
الوصف
تدمد:2051-1426
DOI:10.1136/jitc-2020-000848